Haloperidol is named as an intervention in 2 current clinical trials in our Canada and Brazil registers. 1 is recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Centre for Addiction and Mental Health (1). The most-studied condition is Brain Insulin Sensitivity.
Haloperidol was first approved in the US on 12 Apr 1967.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?
NCT07109245 · ClinicalTrials.gov ↗ · Brain Insulin Sensitivity, Healthy Controls, Cognition
|
Phase 4 | Recruiting | Centre for Addiction and Mental Health | Canada |
|
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
NCT03743649 · ClinicalTrials.gov ↗ · Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm
|
Phase 2/3 | Active, closed | M.D. Anderson Cancer Center | Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Haloperidol on the HPRA medicines list.
No entry for Haloperidol in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Centre for Addiction and Mental Health | 1 |
| M.D. Anderson Cancer Center | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Brazil | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Canada and Brazil registers name Haloperidol (also registered as McN-JR-1625) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Centre for Addiction and Mental Health (1) and M.D. Anderson Cancer Center (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Haloperidol, for example Haloperidol 5mg/ml Solution for Injection (Mercury Pharmaceuticals (Ireland) Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Haloperidol has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Haloperidol works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Haloperidol works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Haloperidol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.